GAAP Financial Statements
Aptose Biosciences Inc. (APTOF)
3 quarters · 1 annual periods · CIK 0000882361
Quarterly (3)
| Period | Form | Revenue | Gross Profit | Op. Income | Net Income | EPS (Basic) | EPS (Dil.) | Assets | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2025 | 10-Q | — | — | — | -$5.1M | $-2.01 | $-2.01 | $6.3M | $613.0K |
| Q2 FY2025 | 10-Q | — | — | — | -$7.0M | $-2.76 | $-2.76 | $5.6M | $553.0K |
| Q1 FY2025 | 10-Q | — | — | — | -$5.5M | $-2.61 | $-2.61 | $7.5M | $4.7M |
Annual (1)
| Period | Form | Revenue | Gross Profit | Op. Income | Net Income | EPS (Basic) | EPS (Dil.) | Assets | Cash |
|---|---|---|---|---|---|---|---|---|---|
| FY FY2024 | 10-K | — | — | — | -$25.4M | $-36.38 | $-36.38 | $10.1M | $6.2M |
Source: SEC EDGAR XBRL filings. Per-period figures are pulled from the original 10-Q / 10-K / 20-F submissions. Balance-sheet items (Assets, Cash, Equity) are point-in-time at period end.